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Background: Overexpression of the human epidermal growth factor receptor (HER) 2 is associated with poor
prognosis and shortened survival in breast cancer patients. HER2 is a potent activator of several signaling pathways
that support cell survival, proliferation and metabolism. In HER2-positive breast cancer there are most likely
unexplored proteins that act directly or indirectly downstream of well established pathways and take part in tumor
development and treatment response.
Methods: In order to identify novel copy number variations (CNVs) in HER2-positive breast cancer whole-genome
single nucleotide polymorphism (SNP) arrays were used. A PCR-based loss of heterozygosis (LOH) assay was
conducted to verify presence of deletion in HER2-positive breast cancer cases but also in HER2 negative breast
cancers, cervical cancers and lung cancers. Screening for mutations was performed using single-strand
conformation polymorphism (SSCP) followed by PCR sequencing. Protein expression was evaluated with
immunohistochemistry (IHC).
Results: A common deletion at chromosome Xq24 was found in 80% of the cases. This locus harbors the gene
solute carrier (SLC) family 25A member 43 (SLC25A43) encoding for a mitochondrial transport protein. The LOH
assay revealed presence of SLC25A43 deletion in HER2-positive (48%), HER2-negative (9%), cervical (42%) and lung
(67%) cancers. HER2-positive tumors with negative or low SLC25A43 protein expression had significantly lower
S-phase fraction compared to tumors with medium or high expression (P= 0.024).
Conclusions: We have found deletion in the SLC25A43 gene to be a common event in HER2-positive breast cancer
as well as in other cancers. In addition, the SLC25A43 protein expression was shown to be related to S-phase
fraction in HER2-positive breast cancer. Our results indicate a possible role of SLC25A43 in HER2-positive breast
cancer and support the hypothesis of altered mitochondrial function in cancer.
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In approximately 20% of primary breast cancers, the
tumor cells have acquired a capacity to increase their
survival and proliferation by overexpressing the human
epidermal growth factor receptor (HER) 2 [1,2]. This
overexpression of the HER2 protein is in the majority of
cases caused by gene amplification [3]. Patients diagnosed
with a HER2-positive tumor have in general a higher risk
for relapse, shorter time to disease progression, and
poorer survival [1,4,5]. For over a decade, the recombin-
ant humanized monoclonal antibody Trastuzumab has
been used in clinic for treatment of HER2-positve breast
cancer which has improved the outcome for these
patients [6]. However, acquired resistance to Trastuzu-
mab is common among patients who initially respond,
even when combined with chemotherapy [7-9]. For
patients with tumor progression after treatment with
Trastuzumab, lapatinib provides a new treatment option.
Lapatinib is a small molecule that competitively binds to
HER2 but also to the family member HER1, and thereby
decreases activation of downstream signals [6].
Several signaling pathways associated with cell pro-
liferation, cell growth, differentiation, survival and
metabolism are activated by the HER-family [2]. The
Phoshatidylinositol-3-kinase (PI3K) pathway has been
identified to have a significant role in HER2-positive
breast cancer as well as in the development and progres-
sion of other cancers. Studies have shown that the PI3K
pathway is frequently perturbed as a result of genetic
alterations such as activating mutations in the PIK3CA
gene [10], or mutation or deletion of the negative regula-
tor phosphatase and tensin homologue (PTEN) [11,12].
These genetic alterations can lead to constitutive activa-
tion of the PI3K pathway and thereby contribute to treat-
ment failure [13,14]. The HER2 network contributes to a
plethora of cellular functions and there are most likely
unexplored proteins acting directly or indirectly of down-
stream pathways affecting tumor development and treat-
ment response.
The aim of the study was to identify novel copy number
variations (CNVs), underlying development and progres-
sion of HER2-positive breast cancer, using whole-genome
single nucleotide polymorphism arrays. The result
revealed a common deletion of the gene encoding for the
inner mitochondrial membrane transporter, solute carrier
(SLC) family 25A member 43 (SLC25A43). Furthermore,




Tumor samples from 85 patients with HER2-positive breast
cancer diagnosed between 1993 and 2008 were included in
the study. Overexpression and/or gene amplification ofHER2 were confirmed using immunohistochemistry (Her-
cepTest™ (Dako, Glostrup, Denmark)) and fluorescence in
situ hybridization (PathVysion HER-2 DNA Probe Kit
(Abbott, Illinois, USA)). Both were performed according
to manufacturer’s protocols. Retrospectively collected pa-
tient characteristics for the HER2-positive breast cancer
cohort are shown in Table 1. The S-phase fraction was
determined using a flow cytometry assay based on Vinde-
löv et al [15] and hormone receptor status was evaluated
using immunohistochemistry. HER2 status, S-phase and
hormone receptors were all assessed at time of diagnosis.
To further analyze presence of loss of heterozygosis in
SLC25A43 in other malignancies, we included cohorts of
HER2-negative breast cancers, cervical cancer and lung
cancer. The cohort of HER2-negative, estrogen receptor
(ER) positive breast cancers consisted of samples from 52
patients with a median age of 64 years. Cervical tumor
samples were obtained from 65 patients (median age of
69 years). Finally, the cohort of lung cancers included 18
female patients (median age 63 years) diagnosed with
adenocarcinoma.
A study layout of the patient material is shown in
Table 2.
The research ethical committee at the Faculty of
Health Science, Linköping, Sweden, approved this study
with no request of an informed consent.
Isolation of DNA
DNA was isolated from approximately 10 mg of fresh
frozen tissue and Buffy coat samples from female blood
donor, using QIAampW DNA Mini Kit or EZI DNA,
QIAGENW Tissue kit (both from QIAGEN Inc., Valen-
cia, CA, USA) followed by purification using BioRobot
EZI workstation (QIAGEN Inc.). DNA concentrations
were quantified using NanoDropW ND-1000 UV–vis
Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE, USA).
Whole-genome assay
Whole-genome screening of CNVs was performed using
Gene ChipW Mapping 250 K Assay Kit (Affymetrix, Inc
Santa Clara, CA USA) according to manufacturer’s
protocol. Briefly, 250 ng of DNA was digested with NspI
restriction enzyme. The DNA fragments were then
ligated with an adaptor and PCR amplified with general
primers. The PCR product was purified, quantified and
cleaved to shorter fragments, followed by labeling.
Thereafter, the sample was hybridized to the array and
then stained with a streptavidin-biotin solution. A Gene
Chip Scanner 3000 7 G (Affymetrix) was used to scan
the chip. To generate a segment report, which is a table
where each row corresponds to a segment with copy
number change that deviates from the expected normal,
Genotyping Consol 3.1 (Affymetrix) was used. Array
Table 1 Patient characteristics and the SLC25A43 expression in the HER2-positive breast cancer cohort
Parameters No. of cases total
in the cohort (%)
Mean values of total
cases in the cohort
SLC25A43 expression P-value
Negative/Low Medium/High
All 85 26 45
Patient's age
≤50 years 22 (26)
>50 years 62 (73)
Mean age (years) 58.5 62 58 0.269
ND 1 (1)
Tumour size
≤2 cm 33 (39)
>2 cm 50 (59)
Mean size (mm) 28 25 30 0.13
ND 2 (2)
S-phase
Include cases 70 (82)
Mean S-phase (%) 10.7 9.4 12.6 0.024
ND 15 (18)
LN metastasis
Negative 27 (32) 8 15 0.859
Positive 55 (65) 17 29
ND 3 (4)
ER status
Negative 38 (45) 12 20 0.951
Positive 41 (48) 13 21
ND 6 (7)
PgR status
Negative 45 (53) 16 24 0.659
Positive 33 (39) 9 17
ND 7 (8)
LN, lymph node; ER, oestrogen receptor; PgR, progesterone receptor; ND, not determined.
Table 2 Study layout of patient material








Lung cancer (♀)a 18
a, patients used for LOH analysis; BC, breast cancer; SNP, single nucleotide
polymorphism; LOH, loss of heterozygosity; IHC, immunohistochemistry.
Tina et al. BMC Cancer 2012, 12:350 Page 3 of 9
http://www.biomedcentral.com/1471-2407/12/350data from forty-six female individuals, available from the
International Hap Map project, were used as controls
for known CNV regions. To generate the segment report,
three different criteria were applied by setting different
values of the parameters provided by the application.
One of the parameters is defined as the number of SNPs
within the segment. By setting the value of this parameter
to five, we introduce constraints to only identify seg-
ments with a minimum of five SNPs within the segment.
The other parameter defined the size of the reported seg-
ment to a minimum size of 100 kbp. Finally, a parameter
for CNV overlap was set to report all segments with up
to 50% overlap with known CNV regions. For each seg-
ment, there is an indication of loss or gain, depending on
whether the copy number change correspond to a
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ther bioinformatics analysis consisted of selecting the
most frequent aberrations, present in a minimum of 10
tumors, and applying clustering tools to find common
patterns of genetic changes among different patients [16].
Loss of heterozygosis assay
Loss of heterozygosis (LOH) analysis of the SLC25A43
gene was carried out by a PCR- restriction fragment
length polymorphism (PCR-RFLP) based method. A
polymorphic site, common among the European/Scandi-
navian population (SNP ID: rs217978), between exon 1
and 2 in the SLC25A43 gene was chosen for the analysis.
PCR amplification was performed in a final reaction vol-
ume of 20 μl containing 25-50 ng of DNA, 1x TopTaq
PCR buffer (1.5 mM MgCl2 (Qiagen) 0.2 mM of each
dNTP, 0.025 U TopTaq DNA polymerase (Qiagen), 1x
Q-solution™ (Qiagen) and 1 μM of primers flanking the
SNP (5’-GCATTGGGAGAATGAGGAGT-3’, HEX5’-
CTGTTGTGCTGCTTGCCTTC-3’ respectively). Amp-
lification was carried out using the following conditions:
initial denaturation (94°C for 3 min), followed by
35 cycles of denaturation (94°C for 30 sec), annealing
(60°C for 30 sec) and extension (72°C for 60 sec, 5) end-
ing with a final extension at 72°C for 10 min. The
101 bp PCR product was then cleaved at the poly-
morphic site using Acc1 (New England BioLabs Inc.,
Ipswich, MA, US) at 37°C for 8 hours followed by heat
inactivation at 80°C for 20 minutes. The cleaved products
were resolved by 3% agarose (w/v) gel electrophoresis
and all samples heterozygous for rs.217978 were selected
for capillary electrophoresis in an ABI PrismW 3130 Gen-
etic Analyzer (Applied Biosystems, CA, USA). GeneMap-
per v 4.0 software was used for the analysis of the area
under the peak which represents the amount of each al-
lele. For each sample, an allelic ratio (AR) was calculated
by dividing the peak area of allele 1 by the peak area of
allele 2. To determine a reference interval (mean allelic
ratio ± 1.96SD), 29 heterozygous female blood donors
were used and tumor samples with an AR within the
reference interval were defined to have retention of het-
erozygosis (ROH) while samples outside the range were
considered to have LOH.
Mutation analysis
All exons of the SLC25A43 gene were screened in
HER2-positve breast cancer samples using single-strand
conformation polymorphism (SSCP). The primary PCR
was performed in a total volume of 20 μl PCR contain-
ing 25-50 ng DNA, 1x TopTaq PCR buffer (1.5 mM
MgCl2, 0.2 mM of each dNTP) (Qiagen), 0.025U TopTaq
DNA polymerase (Qiagen), 1x Q-solution™ (Qiagen) and
1 μM of each primer (Additional file 1: Table S1). Amp-
lification was carried out using the following conditions:initial denaturation (94°C for 3 min), followed by
30 cycles of denaturation (94°C for 30 sec), annealing
(59 or 60°C for 30 sec) and extension (72°C for 60 sec)
ending with a final extension (72°C for 10 min). These
amplicons were then radiolabeled for single-strand con-
formation polymorphism (SSCP) in a secondary PCR,
where 2 μl of the primary PCR product was amplified
for 12 cycles in the presence of deoxyadenosine 5’-
triphosphate, α-33P (Perkin Elmer, Boston, MA, USA).
Fragments were run both on a non-denaturing 6% poly-
acrylamide gel at 6 W (3000 V, 300 mA) for 16-18 hours
and on a MDE™ gel (Mutation Detection Enhancement,
BMA products, Rockland, ME) for 8 hours at room
temperature. The gel was dried and auto exposed to
X-ray film (35 x 45 cm, Kodak BMS-1) in an exposure
cassette using Trans Screen LE intensifier at -80°C for
1-2 days. The DNA fragments with mobility shifts
were excised and preamplifier for sequencing by PCR.
Cycle sequencing was performed using a BigDyeW Ter-
minator kit (Applied Biosystems, CA, USA) on 1 μl of
clean PCR product (PCR-M ™ clean up system, VIO-
GENE, Sunnyvale, CA, USA) in a final volume of 10 μl
containing 0.5x BigDye Terminator v1.1 Ready Reaction
Mix, 0.5x BigDye Sequencing buffer, 0.16 μM of forward
and reverse primers in a 2720 thermal cycler (Applied
Biosystems, CA, USA) using following conditions; Initial
denaturation (96°C for 60 sec), followed by 25 cycles of
denaturation (96°C for 10 sec), annealing (50°C for 5 sec)
and extension (60°C for 4 sec). The extension products
were purified using an ethanol (95%) - Sodium acetate
(3 M, pH 4.6) precipitation technique followed by capil-
lary electrophoresis in an ABI PrismW 3130 Genetic
Analyzer (Applied Biosystems CA, USA). A partial se-
quence of pGEM-3Zf (+) was used as control sequence.
The results were analyzed using Sequencing Analysis
v5.2 (CA, USA) and ChromasPro v1.34 developed by
Technelysium Pty, Ltd.
Immunohistochemistry
Formalin-fixed tissue micro array (TMA) sections were
deparaffinised, rehydrated and washed. Endogenous per-
oxidase were blocked using 3% hydrogen peroxide,
followed by heat-induced antigen retrieval in 1 mM EDTA
buffer pH 8.0 for 20 minutes. Slides were incubated with
primary antibody rabbit polyclonal anti-SLC25A43 (1:500)
(raised against the C-terminal part of the protein (Agri-
sera, Vännäs, Sweden)) for 20 minutes at room
temperature. Slides were washed and subsequently incu-
bated with horseradish peroxidase-conjugated secondary
antibody (Dako) for 20 minutes at room temperature.
Bound antibodies were visualized using diaminobenzidine
(DAB) chromogen (Dako) and counterstained with
haematoxylin. The specificity of the antibody was tested
by western blot with the synthetic peptide used as the
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membrane protein ATP5B was used as comparison for
localization of immunostaining (Figure 1a). For scoring of
the SLC25A43 expression, an intensity scale was applied
using the following criteria: 0: negative expression, 1+:
low expression, 2+: medium expression and 3+: high ex-
pression (Figure 1b). The slides were scored by two inde-
pendent observers without knowledge about clinical and
pathological data.Statistical analysis
To evaluate the association between LOH, IHC and ER/
PgR-status or positive lymph nodes, χ2 test were per-
formed. Differences in age, tumor size or S-phase be-





Figure 1 Protein expression of SLC24A43 in HER2-positive tumours o
Comparison of staining localisation and pattern between SLC25A43 and th
(x40 Objective) (a). The four different levels of SLC24A43 expression in HER
showing 200 μm.Student’sT-test. Statistical significance was set at P < 0.05.
SPSS 17.0 statistical software for Windows (SPSS Inc.,
Chicago, IL, USA) was used for all tests.Results
Deletion at Xq24 in HER2-positive breast cancer
In our search for novel CNVs in HER2-positive breast
cancers, 25 tumors were screened using a whole-genome
array. To identify the most common CNVs, we only pro-
ceeded with events that were found in at least ten of the
tumors. Using this approach we obtained CNV in 40 dif-
ferent loci whereof 16 were amplifications and 24 dele-
tions. Most of the loci with amplification were seen in
chromosome 1q but there were also amplifications
found in specific loci in 3q, 8q, 12q, 17q and in bothHigh
Low
ATP5B
n TMA. Staining of SLC25A43 is localised to the cytoplasm of the cells.
e mitochondrial inner membrane protein ATP5B in breast tumours
2-positive tumours used for scoring (x20 Objective) (b). Scale bar is
Table 3 Loss of heterozygosity in different tumours
Type of cancer Heterozygous patients (%) Patients with LOH (%)
HER2-positive 33/85 (39) 16/33 (48)
HER2-negative 22/52 (42) 2/22 (9)
Cervical cancer 26/65 (40) 11/26 (42)
Lung cancer (♀) 6/18 (33) 4/6 (67)
LOH, loss of heterozygosity.
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sented at 11q, 17p and Xq. In 80% of the 25 HER2-
positive breast tumors deletion at Xq24 was observed,
covering both previously known genes as well as novel
genes in relation to cancer (Additional file 1: Table S2
and S3). The deletion pattern at Xq24 is shown in
Figure 2. In all these tumors, the deletion at Xq24
encompassed the two genes SLC25A43 and SLC25A5,
which both encodes for inner mitochondrial membrane
transporters of the SLC25 family [17-19]. SLC25A5
translocates adenosine diphosphate (ADP) from the
mitochondrial matrix into the cytoplasm and partially
share its function with the homolog SLC25A6 (91%
amino acid similarity) [17,20]. SLC25A43 is suggested to
be an importer although its preferred substrate is cur-
rently not known [21]. The common deletion found
covering SLC25A43 indicates a possible role of this
gene in HER2-positve breast cancer. Since SLC25A43
has not been previously studied in relation to cancer
we decided to further investigate this finding.Common loss of heterozygosity in SLC25A43
We continued to verify the SLC25A43 deletion identified
by whole-genome array, using a PCR-based LOH assay in
85 HER2-positive breast cancer cases. Cases that showed
a heterozygous pattern after enzymatic cleavage were used
for further LOH analyses (Table 3). Based on the reference
interval (0.39 – 1.25), 48% of the heterozygous cases
showed allelic ratios outside the range and were defined
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Chromosome X
Figure 2 Deletions at Xq24 in HER2-positive cancer. Tumour samples w
end points for the deletion found in 20 of 25 cases at Xq24. The position oLOH and tumor characteristics no statistical significance
was found. Although, age at diagnosis was significantly
higher in the LOH group when compared with the ROH
group, with the mean age of 67 and 49 years, respectively
(P=0.0002). In addition, to evaluate if the deletion was a
general event in cancer among women we added tumor
samples from HER2-negative breast cancer, cervical can-
cer and lung cancer in the LOH analysis. The three
cohorts showed frequencies of 9%, 42% and 67%, respect-
ively (Table 3).
The high frequency of LOH found in SLC25A43
indicated a possible role as a tumor suppressor gene. To
investigate presence of a possible second genetic alter-
ation in the SLC25A43 gene, ensuring complete inactiva-
tion of a tumor suppressor gene [22], we screened 29
HER2-positive breast tumors for mutations. However, we
could not detect any mutation.SLC25A43 expression varies in HER2-positive tumors
Out of the 85 HER2-positive tumors, 71 cases were avail-
able for further analysis using TMA in order to evaluate118400 118600 118800 119000kBp
ere analysed using whole-genome array to identify CNVs. Start and
f SLC25A43 is marked blue on the X-axis.
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tumor cells demonstrated a homogeneous expression of
SLC25A43 within the tumor but the expression varied
widely, spanning from non-existent to very high expres-
sion, between tumors (Figure 1b). Four tumors were
negative and 22 tumors had low expression, while 28
and 17 tumors showed medium and high expression, re-
spectively. In the statistical analysis we combined cases
with negative and low expression (37%) to compare with
a combination of the cases showing medium or high ex-
pression (63%). There was no significant association be-
tween SLC25A43 expression and LOH, which could in
part be explained by the few number of cases with LOH
in the SLC25A43 gene (n = 16) that were available for
comparison. SLC25A43 expression was not associated
with ER status, lymph node metastasis or age at diagnosis
(Table 1). However, cases with negative or low expression
of SLC25A43 did show a significantly lower Synthesis (S)-
phase fraction (mean S-phase 9.4%) compared to cases
with medium or high expression (mean S-phase 12.6%)
(P=0.024) (Table 1, Figure 3).P = 0.0
Figure 3 Boxplot of S-phase distribution and SLC24A43 protein expre
expression (n = 26) and medium/high expression (n = 45) of SLC25A43.Discussion
In this study, a common deletion of the SLC25A43 gene,
located at Xq24, was revealed in HER2-positive breast
cancer using whole-genome array. This novel finding
indicates a possible role of SLC25A43 in HER2-positive
breast cancer through an altered mitochondrial function.
CNVs have previously been reported at Xq in HER2-
positive breast cancer [23,24], supporting our finding.
Deletions in X chromosome are also suggested to be
associated with tumor progression, metastasis and poor
prognosis in breast cancer [25]. We further confirmed
deletion in the SLC25A43 gene in a larger HER2-positive
cohort using a PCR-based LOH assay. Deletion in
SLC25A43 was also found to be present in other types of
cancer in female patients, suggesting it to be a putative
tumor suppressor gene. However, there were no muta-
tions detected within the SLC25A43 gene in our co-
hort. Another possible mechanism for transcriptional
silencing is increased methylation [26,27], and recent
findings show higher methylation in the CpG island of
the SLC25A43 gene in breast cancer in the absence of24
ssion. S-phase fraction in tumours with negative/low protein
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also associated with lower age at diagnosis in HER2-
positive breast cancer [28] while deletion of SLC25A43
was found in tumors from patients with higher age at
diagnosis. In females one of the two X chromosomes is
randomly inactivated by DNA methylation [29], thus the
need of two hits for complete inactivation of SLC25A43
depends on whether the deletion is localized on the
active or inactive X chromosome. The limitation with the
two methods used in the present study to determine
occurrence of SLC25A43 deletion is that they do not dis-
criminate between the active or inactive X chromosome.
When evaluating the protein expression with immu-
nohistochemistry, results showed that SLC25A43 ex-
pression varied between negative to high among
HER2-positive breast cancers and was not associated
with ER status, lymph node metastasis or age at diagno-
sis. A possible explanation for the lack of association be-
tween LOH-status and protein expression could be the
low number of cases available for comparison. It would
therefore be of great interest to expand the cohort in-
cluding cases with deletion in the SLC25A43 gene in the
future. However, in our study the S-phase fraction was
shown to be significantly lower in cases with negative or
low SLC25A43 expression compared with medium or
high expression of SLC25A43. It is currently not possible
to explain the relation between SLC25A43 expression
and S-phase fraction. Mitra et al have shown that the
mitochondria also could have a role in cell cycle regula-
tion [30] but the connection between SLC25A43 and cell
proliferation has to be further elucidated.
The closest relative of SLC25A43 is the Coenzyme A
(CoA) transporter SLC25A16, sharing 29% amino acid se-
quence similarity [18]. The next closest relative,
SLC25A42, has been shown to transport both CoA and
ADP [31]. Even though the function of SLC25A43
remains unexplored, alterations in the expression is likely
to affect mitochondrial function. Mitochondrial dysfunc-
tion in cancer cells was first described by Otto Warburg
in the 1920s where he demonstrated an increased glycoly-
sis in the presence of oxygen (aerobic glycolysis) [32].
Today, it is well established that mitochondrial dysfunc-
tion have an important role in tumor development and
progression. Hanahan and Weinberg proposed that one of
the hallmark capabilities in cancer cells is their enhanced
resistance to mitochondrial apoptosis [33]. Another hall-
mark is the sustained chronic proliferation found in can-
cer cells as a result of evading the strictly controlled
production and release of growth factors as well as dysre-
gulation of receptors and downstream signals [33].
Our findings of deletion in the SLC25A43 gene to-
gether with varied SLC25A43 protein expression in
HER2-positive breast cancers supports the role of altered
mitochondrial function as a hallmark of cancer.Conclusions
To the best of our knowledge, this is the first report to
demonstrate a common deletion in SLC25A43 in HER2-
positive breast cancer as well as in other cancers, sug-
gesting that it might be an important genetic event. The
SLC25A43 protein expression was found to be related to
S-phase fraction indicating a possible role of this mito-
chondrial protein in cell proliferation.
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